Cedar Pollen Allergy - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Cedar Pollen Allergy - Pipeline Review, H2 2014', provides an overview of the Cedar Pollen Allergy's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cedar Pollen Allergy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cedar Pollen Allergy and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Cedar Pollen Allergy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cedar Pollen Allergy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cedar Pollen Allergy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cedar Pollen Allergy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cedar Pollen Allergy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cedar Pollen Allergy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Cedar Pollen Allergy Overview 7 Therapeutics Development 8 Pipeline Products for Cedar Pollen Allergy - Overview 8 Pipeline Products for Cedar Pollen Allergy - Comparative Analysis 9 Cedar Pollen Allergy - Therapeutics under Development by Companies 10 Cedar Pollen Allergy - Therapeutics under Investigation by Universities/Institutes 11 Cedar Pollen Allergy - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Cedar Pollen Allergy - Products under Development by Companies 14 Cedar Pollen Allergy - Products under Investigation by Universities/Institutes 15 Cedar Pollen Allergy - Companies Involved in Therapeutics Development 16 Allergy Therapeutics plc 16 Anergis SA 17 Biomay AG 18 Circassia Pharmaceuticals plc 19 Immunomic Therapeutics, Inc. 20 Japan Tobacco Inc. 21 REGiMMUNE Corporation 22 Stallergenes S.A. 23 Cedar Pollen Allergy - Therapeutics Assessment 24 Assessment by Monotherapy Products 24 Assessment by Target 25 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 AllerJ - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Drug for Japanese Cedar Pollen Allergy - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Drugs for Cedar Pollen Allergy - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Japanese Cedar Hypoallergenic Vaccine - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 JCC-LAMP-Vax - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 JRC-LAMP-Vax - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 MC-LAMP-Vax - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Pollinex Quattro Japanese Cedar - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 RGI-1001 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 TO-206 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Vaccine for Cedar Pollen Allergy - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Vaccine for Cedar Pollen Allergy - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Cedar Pollen Allergy - Recent Pipeline Updates 43 Cedar Pollen Allergy - Dormant Projects 44 Cedar Pollen Allergy - Product Development Milestones 45 Featured News & Press Releases 45 Apr 24, 2013: Immunomic Therapeutics Announces Interim Data Analysis Of Phase I Study To Treat Japanese Red Cedar Allergy 45 Nov 08, 2012: Immunomic Therapeutics Doses First Patient In Phase I Clinical Trial Of JRC-LAMP-Vax Vaccine To Treat Japanese Red Cedar Allergy 45 Appendix 47 Methodology 47 Coverage 47 Secondary Research 47 Primary Research 47 Expert Panel Validation 47 Contact Us 48 Disclaimer 48
List of Tables Number of Products under Development for Cedar Pollen Allergy, H2 2014 8 Number of Products under Development for Cedar Pollen Allergy - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 10 Number of Products under Investigation by Universities/Institutes, H2 2014 11 Comparative Analysis by Clinical Stage Development, H2 2014 12 Comparative Analysis by Early Stage Development, H2 2014 13 Products under Development by Companies, H2 2014 14 Products under Investigation by Universities/Institutes, H2 2014 15 Cedar Pollen Allergy - Pipeline by Allergy Therapeutics plc, H2 2014 16 Cedar Pollen Allergy - Pipeline by Anergis SA, H2 2014 17 Cedar Pollen Allergy - Pipeline by Biomay AG, H2 2014 18 Cedar Pollen Allergy - Pipeline by Circassia Pharmaceuticals plc, H2 2014 19 Cedar Pollen Allergy - Pipeline by Immunomic Therapeutics, Inc., H2 2014 20 Cedar Pollen Allergy - Pipeline by Japan Tobacco Inc., H2 2014 21 Cedar Pollen Allergy - Pipeline by REGiMMUNE Corporation, H2 2014 22 Cedar Pollen Allergy - Pipeline by Stallergenes S.A., H2 2014 23 Assessment by Monotherapy Products, H2 2014 24 Number of Products by Stage and Target, H2 2014 25 Number of Products by Stage and Route of Administration, H2 2014 27 Number of Products by Stage and Molecule Type, H2 2014 29 Cedar Pollen Allergy Therapeutics - Recent Pipeline Updates, H2 2014 43 Cedar Pollen Allergy - Dormant Projects, H2 2014 44
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.